Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Researchers have discovered a new use for an old drug as a potential treatment for prostate cancer.
The findings are published in the journal The Prostate.
Since the 1940s, androgens have been linked to prostate cancer, and decades of work since have focused on androgen receptor (AR), a nuclear receptor transcription factor.
Although AR drives prostate cancer, inhibiting it induces remission for only a short time.
Investigators have found that riluzole, a drug approved for the treatment of amyotrophic lateral sclerosis, promotes the degradation of AR through a distinct pathway.
The findings suggest that riluzole should be investigated clinically for prostate cancer and predict that it may be effective for both early stage and advanced disease," said senior author Dr. Shahriar Koochekpour, of Roswell Park Comprehensive Cancer Centre.
Source: Wiley
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.